Cargando…
ABT-888 restores sensitivity in temozolomide resistant glioma cells and xenografts
BACKGROUND: Temozolomide (TMZ) is active against glioblastomas (GBM) in which the O6-methylguanine-DNA methyltransferase (MGMT) gene is silenced. However, even in responsive cases, its beneficial effect is undermined by the emergence of drug resistance. Here, we tested whether inhibition of poly (AD...
Autores principales: | Yuan, Alice L., Ricks, Christian B., Bohm, Alexandra K., Lun, Xueqing, Maxwell, Lori, Safdar, Shahana, Bukhari, Shazreh, Gerber, Amanda, Sayeed, Wajid, Bering, Elizabeth. A., Pedersen, Haley, Chan, Jennifer A., Shen, Yaoqing, Marra, Marco, Kaplan, David R., Mason, Warren, Goodman, Lindsey D., Ezhilarasan, Ravesanker, Kaufmann, Ascher B., Cabral, Matthew, Robbins, Steve M., Senger, Donna L., Cahill, Daniel P., Sulman, Erik P., Cairncross, J. Gregory, Blough, Michael D. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Public Library of Science
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6112648/ https://www.ncbi.nlm.nih.gov/pubmed/30153289 http://dx.doi.org/10.1371/journal.pone.0202860 |
Ejemplares similares
-
Evaluation of Concurrent Radiation, Temozolomide and ABT-888 Treatment Followed by Maintenance Therapy with Temozolomide and ABT-888 in a Genetically Engineered Glioblastoma Mouse Model
por: Lemasson, Benjamin, et al.
Publicado: (2016) -
Evaluation of poly (ADP-ribose) polymerase inhibitor ABT-888 combined with radiotherapy and temozolomide in glioblastoma
por: Barazzuol, Lara, et al.
Publicado: (2013) -
ABT-888 enhances cytotoxic effects of temozolomide independent of MGMT status in serum free cultured glioma cells
por: Balvers, Rutger K, et al.
Publicado: (2015) -
Evaluation of ABT-888 in the amelioration of α-synuclein fibril-induced neurodegeneration
por: Hastings, Lyndsay, et al.
Publicado: (2022) -
The PARP inhibitor ABT-888 potentiates darbazine-induced cell death in carcinoids
por: Somnay, Yash, et al.
Publicado: (2016)